Clinical Trials Logo

Post-ERCP Acute Pancreatitis clinical trials

View clinical trials related to Post-ERCP Acute Pancreatitis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06260878 Not yet recruiting - Clinical trials for Post-ERCP Acute Pancreatitis

Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis

STRIPE
Start date: September 1, 2024
Phase: Phase 4
Study type: Interventional

This study will explore the efficacies of several practical short-term (peri-procedural) intravenous fluid regimens in the prevention of post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). PEP is the most common serious ERCP-related adverse event (AE), occurring in 5-15% of patients, and associated with significant morbidity, mortality, and healthcare utilization. Given the current lack of data on effectiveness of short-term fluid regimens in PEP prevention to inform practice, the results of the proposed study have the strong potential to impact ERCP practices worldwide, whether positive or negative.

NCT ID: NCT04770857 Not yet recruiting - Clinical trials for Post-ERCP Acute Pancreatitis

Evaluation of Post-ERCP Pain as a Predictor for Post-ERCP Pancreatitis

PEP-PREPARE
Start date: September 1, 2021
Phase:
Study type: Observational

Pancreatitis is the most common complication after ERCP, although its frequency varies significantly depending on the study from < 2% up to 40%. Based upon data from studies that have included unselected patients, post-ercp pancreatitis (PEP) is mild, moderate, and severe in 45%, 44%, and 11% of cases, respectively. Dysfunction of the sphincter Oddi, female gender, younger age, previous history of pancreatitis, prolonged procedure time and pancreatic guidewire passages are well-known independent risk factors for PEP. This study will assess whether the development of PEP can be predicted by Visual analogue scale (VAS) level 1 hour after ERCP.

NCT ID: NCT03215862 Not yet recruiting - Clinical trials for Post-ERCP Acute Pancreatitis

Lactated Ringer's Solution to Prevent Post-ERCP Pancreatitis

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

This is a randomized, double-blinded, controlled trial. This study is a head to head comparison of normal saline (NS) infusion versus Lactated Ringer's (LR) infusion in patients, with the primary outcome of post-ERCP pancreatitis occurrence. Patients will be randomized to either the NS infusion group or the LR infusion group. IVF will be started pre-procedurally and will be continued throughout the procedure. A IVF bolus will be given at the end of the procedure and then continued as a continuous infusion. Our null hypothesis is that there will be no significant difference in the rate of occurrence of post-ERCP pancreatitis between the infusion of LR and NS solutions. Our alternative hypothesis is that patients receiving LR solution infusion will experience a decreased rate of post-ERCP pancreatitis compared to patients receiving NS solution infusion.